Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial.
about
Pragmatic use of insulin degludec/insulin aspart co-formulation: A multinational consensus statementInsulin degludec and insulin aspart: novel insulins for the management of diabetes mellitusInsulin Degludec Aspart: The First Co-formulation of Insulin AnaloguesIdentifying and meeting the challenges of insulin therapy in type 2 diabetes.Insulin degludec aspart: One-year real world experience.Protamine zinc insulin combined with sodium selenite improves glycometabolism in the diabetic KKAy miceTwice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with Type 2 diabetes.Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial.Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes.Investigation of the Physico-Chemical Properties that Enable Co-Formulation of Basal Insulin Degludec with Fast-Acting Insulin Aspart.Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST® T1).Efficacy and safety of switching from basal insulin to once-daily insulin degludec/insulin aspart in Japanese patients with inadequately controlled type 2 diabetes: A 4-week, randomized, open-label, treat-to-target study.15 Years of Experience with Biphasic Insulin Aspart 30 in Type 2 Diabetes.
P2860
Q26745609-E80C909F-EA59-4536-9436-F6A4D93757CEQ26777076-6507006A-EBF1-43FC-B005-A962AA2732A2Q33785168-EEFD4E9E-ED78-45C1-8A51-9E5408C7C04EQ33863413-8DF06431-8686-40A2-A9EC-7E51C05EFB6BQ36867457-EB57B444-65AE-45BA-9455-E580DF0B6FF4Q36925407-E7E349D7-0530-48BE-866B-CEC7D32A4E48Q37337300-22F85EF5-1432-445A-B117-025462CF368DQ37677863-59DE9B68-2C7F-4E6B-8CD7-AD6426950EB3Q38241834-D81D8507-5A31-433F-885E-9B4A984C0D14Q41558812-32E5D2CD-B88E-4D82-BCD1-041E46BDDB35Q42329441-7F4F1E78-A6F7-40AC-A7A0-538846FAD4B0Q42691318-03895DE5-C34C-4BAF-91D9-17867F81D6F9Q52691073-EB0A8377-3924-40E3-816C-4D948F49EE3E
P2860
Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Comparison of a soluble co-for ...... diabetes: a randomised trial.
@ast
Comparison of a soluble co-for ...... diabetes: a randomised trial.
@en
type
label
Comparison of a soluble co-for ...... diabetes: a randomised trial.
@ast
Comparison of a soluble co-for ...... diabetes: a randomised trial.
@en
prefLabel
Comparison of a soluble co-for ...... diabetes: a randomised trial.
@ast
Comparison of a soluble co-for ...... diabetes: a randomised trial.
@en
P2093
P2860
P356
P1476
Comparison of a soluble co-for ...... 2 diabetes: a randomised trial
@en
P2093
Allan Vaag
Edward Franek
Jean-Paul Donnet
Jianping Weng
Lars Endahl
Lawrence A Leiter
Leo Niskanen
Taner Damci
Trine Vang Skjøth
P2860
P304
P356
10.1530/EJE-12-0293
P577
2012-06-01T00:00:00Z